SEC Form D Coverage: Element Genomics $5.10 million Fundraising. John Oxaal Submitted Nov 2 Form D

Health Care Element Genomics, Inc. - John Oxaal

Element Genomics Financing

Element Genomics, Inc., Corporation just had published form D for $5.10 million debt financing. This is a new filing. Element Genomics was able to finance itself with $4.85 million. That is 95.10% of the fundraising. The total private financing amount was $5.10 million. The form was filed on 2016-11-02. The reason for the financing was: Other than the payment of salaries and other compensation and benefits no officer, director, or promoter will receive any payments from the proceeds of this offering.. The fundraising still has about $250,000 more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Element Genomics is based in North Carolina. The company’s business is Other Health Care. The D form was filed by John Oxaal President and CEO. The company was incorporated in 2015. The filler’s address is: 300 North Duke Street, Bay 49-1, Durham, Nc, North Carolina, 27701. John Oxaal is the related person in the form and it has address: 300 North Duke Street, Bay 49-1, Durham, Nc, North Carolina, 27701. Link to Element Genomics Filing: 000168110116000002.

Analysis of Element Genomics Offering

On average, companies in the Other Health Care sector, sell 68.60% of the total offering amount. Element Genomics sold 95.10% of the offering. The fundraising is still open. Could this mean that the trust in Element Genomics is high? The average financing size for companies in the Other Health Care industry is $1.16 million. The total amount raised is 318.10% bigger than the average for companies in the Other Health Care sector. The minimum investment for this offering is set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Element Genomics Also

The Form D signed by John Oxaal might help Element Genomics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment